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Abstract 
Background: Malaria is one of the most life-threatening health problems worldwide and treatment has been com-
promised by drug resistance. Identifying lead molecules from natural products might help to find better anti-malarial 
drugs, since those obtained from natural sources are still effective against malarial parasites. This study aimed at 
investigating the in vivo antiplasmodial activity of crude extract of the leaves of Ajuga remota together with its safety 
in mice models.
Methods: In vivo parasite growth inhibitory effect of crude extract was assessed in mice inoculated with Plasmodium 
berghei (ANKA strain). The in vivo antiplasmodial activity of the test extract was performed against early infection 
(4-day suppressive test), curative effect against established infection and prophylactic effect against residual infection. 
Acute and sub-acute toxicity were carried out according to OECD guidelines.
Results: In vivo parasite growth inhibition effect of hydroethanolic crude extract of A. remota was evaluated at 30, 50 
and 100 mg/kg dose levels. It suppressed parasitaemia by 77.34% at 100 mg/kg dose level in the 4-day test. In cura-
tive and prophylactic potential tests, it suppressed parasitaemia by 66.67 and 59.66% at 100 mg/kg dose level, respec-
tively. In vivo toxicity tests revealed no toxicity. All parasitaemia suppressions were statistically significant at P < 0.05 as 
compared to the vehicle-treated group. The crude extract also prolonged survival time in a dose dependent manner.
Conclusions: The investigation results suggest that the leave extract of Ajuga remota possesses antimalarial activity.
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Background
Malaria is one of the major infectious diseases responsi-
ble for the high rate of mortality and morbidity in devel-
oping countries. It is caused by Apicomplexan protozoan 
parasites of the genus Plasmodium [1]. The disease bur-
den is very alarming in the sub-Saharan countries and 
mainly affects children less than five years of age, which 
accounts for about 78% of all global deaths [2]. Malaria 
also causes series adverse effects during pregnancy for 
both mother and infant, such as maternal anaemia, low 
birth weight, and increased perinatal and infant mortality 
[3]. This infectious disease is highly fatal unless diagnosed 
and treated in a timely fashion. It may also predisposes 
the patient to opportunistic infections [4].
Ajuga remota belongs to a genus of about 40–50 spe-
cies of annual and perennial herbaceous flowering plants 
in the Mint (Lamiaceae) family [5, 6]. The aqueous or 
alcohol extract of fresh or dried leaves of A. remota have 
been traditionally used for the treatment of diabetes, 
malaria, pain and fevers, toothache, skin disease, hyper-
tension, stomach ache, pneumonia, liver problem and 
swelling of legs [7, 8]. Various compounds have been 
isolated from the leaves of Ajuga remota, including five 
different neo-clerodane diterpenes [8, 9]. Sterols (ajuga-
lactone), triterpenoid (ergosterol-5, 8-endoperoxide and 
iridoid glycoside (8-O-acetylharpagide) were also isolated 
from the plant, as well as phenolic acids, flavonoids and 
saponins [8, 10]. The plant has wide traditional medicinal 
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applications, and the present study was designed to con-
firm its anti-malarial efficacy and safety of its use.
Methods
Plant material preparation
Fresh leaves of A. remota (Labiatae) were collected in 
October 2012 around Entoto area, North of Addis Ababa. 
The leaves of the plant material were identified by a tax-
onomist at the National Herbarium, College of Compu-
tational and Natural Sciences, Addis Ababa University. A 
voucher number of AR-001 was given and deposited at 
the herbarium for future reference. The study was per-
formed after obtaining ethical approval from institutional 
review board of the College of Health Sciences, Addis 
Ababa University.
Extraction
The leaves were air dried at room temperature under 
shade and ground to a powder using pestle and mor-
tar. A total of 250 g dried leaves were macerated in 80% 
of 2.5-l ethanol (1:10 w/v) for 72 h. The extraction was 
carried out by using an orbital shaker at 120  rpm. The 
mixture was first filtered with gauze and then Whatman 
filters paper No. 1 (Whatman®, England). The mark was 
re-macerated for another 72  h twice and filtered. The 
combined ethanol filtrates were then concentrated by 
rotary evaporator (Buchi Rota vapor, Switzerland) at a 
temperature of 40  °C. The residual water was removed 
by lyophilizer (operon, Korea vacuum limited, Korea) 
at −44 °C. The extract was dark green lustrous gummy 
substance. After drying, a total of 27.32 g of dry extract 
was collected. The extract was stored in tightly closed 
bottle container in a refrigerator at −20  °C until used 
[11].
In vivo toxicity assay
Acute toxicity test
The hydroethanolic crude extracts of A. remota was 
tested in non-infected female Swiss albino mice aged 
6–8  weeks and weighing 23–31  g. For each crude 
extract, 10 mice were used by randomly dividing them 
into two groups of 5 mice per group. The mice were 
starved for 3  h before the experiment began and only 
allowed water ad  libitum. After 3  h, the extract was 
administered orally in a single dose. The mice in group 
I was given 0.2  ml of 2000  mg/kg body weight of the 
extract. The mice in the control groups received 0.2 ml 
of the vehicle (distilled water) used for dissolving the 
extract. Then, the mice were observed continuously for 
1 h, followed by 4 h observations for 24 h and thereaf-
ter daily for 14  days, for any manifestation of toxicity 
[12].
Sub‑acute toxicity test
For sub-acute toxicity studies, weight and haematologi-
cal parameter like packed cell volume (PCV) were deter-
mined before and after treatment. PCV was determined 
by micro-haematocrit reader (Hawksley and Sons, Eng-
land). The extracts in each case were administered orally 
for 4 days (i.e., D0 to D3). The mice were grouped ran-
domly, five mice per group. The mice in group I, II and 
III were given 500, 750 and 1000  mg/kg body weight 
in single dose volume of 0.2  ml of each crude extract, 
respectively. The control group received 0.2 ml of dH2O. 
The data were recorded to check for reduction in PCV 
and weight losses on day 0 and 3 (12 h after administra-
tion of the last dose) and thereafter, the mice were closely 
observed for 1 month [12].
In vivo antiplasmodial activity assay
Parasite inoculation
Albino mice earlier infected with Plasmodium berghei, 
ANKA strain, (parasitaemia level of 20–30%) were used 
as donor. The donor mice were then sacrificed with ethyl 
ether anesthesia and blood was collected by cardiac 
puncture into heparinized vacutainer tube. The blood 
was then diluted with physiological saline (0.9%) based 
on parasitaemia level of the donor mice and the red blood 
cell (RBC) count of normal mice, in such a way that 1 ml 
blood contains 5 ×  107 infected RBC [13]. Each mouse 
was then given 0.2  ml of this diluted blood intraperito-
neally, which contained 1 × 107 P. berghei infected RBCs.
Grouping and dosing of animals
Four‑day suppressive test
This test was used to evaluate the schizontocidal activity 
of the crude extract against P. berghei infected mice [14]. 
Antiplasmodial activity of the test extract was performed 
in a 4-days suppressive standard test. Male Swiss Albino 
mice weighing 22–29 g were inoculated on the first day 
(Day 0), intraperitoneally, with 0.2 ml of infected blood. 
The mice were then divided randomly into five groups 
of six mice per group. Three groups (II, III and IV) were 
assigned as test groups whereas the other two groups 
(I & V) were used as control (negative and positive) 
groups. Three hours after infection 30, 50 and 100  mg/
kg/day of hydroalcoholic crude extract of A. remota were 
administered to the test groups. Chloroquine at the dose 
of 25  mg/kg/day and an equivalent volume of vehicle 
(0.2 ml 7% tween 80 solution) were administered to the 
positive and negative control groups, respectively, for 
four consecutive days (Day 0–3). On the fifth day (on day 
4, 24  h after the last dose i.e. 96  h post-infection), thin 
blood smears were made from the tail of each mouse, 
fixed with methanol and stained with 10% Giemsa. The 
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parasitaemia level was determined by counting the num-
ber of parasitized erythrocytes out of 100 erythrocytes in 
random 8 fields of microscope.
Parasitaemia was determined by light microscopy 
using a 100× objective lens and the following equation:
 Average percentage chemo-suppression was calculated 
as
where A is the average percentage parasitaemia in the 
negative control group and B is the average percent-
age parasitaemia in the test group. The capability of the 
various doses of the crude extract in preventing body 
weights and packed cell volume (PCV) reduction of the 
mice as a result of raise in parasitaemia were followed. 
The weight, PCV and rectal temperature were taken at 
D0 and D4.
Test for curative activity (Rane’s test)
The chemotherapeutic activity of hydroethanolic crude 
extract was carried out in established infection [15]. On 
the first day (Day 0), 0.2 ml standard inocula of 1 × 107 
P. berghei infected erythrocytes were inoculated in mice 
intraperitoneally. Seventy-two hours later (Day 3), mice 
were randomly divided in three test groups (II, III and 
IV) of six mice each. Group I and V were assigned as 
negative and positive controls, respectively. Then, the 
test groups were dosed with 30, 50, 100  mg/kg/day of 
the extract. Negative and positive controls received vehi-
cle (0.2 ml 7% tween 80) and chloroquine 25 mg/kg/day 
orally, respectively. Giemsa-stained thin blood film was 
prepared from the tail of each mouse on days 3 and 7 to 
monitor parasitaemia level.
Test for prophylactic activity
The prophylactic activity of the extract was tested using 
the residual infection procedure [16]. On the first day 
(Day 0), mice were randomized into five groups six mice 
per group. Groups II, III, IV were used for evaluation 
of test samples. Group I and V were used as negative 
and positive controls, respectively. Group II, III and IV 
received oral doses of 30, 50 and 100 mg/kg/day for three 
consecutive days (Day 0–2). Whereas negative and posi-
tive controls received vehicle (0.2  ml 7% tween 80) and 
chloroquine 25  mg/kg/day orally, respectively. On the 
fourth day, all mice were infected with 0.2  ml standard 
inocula of 1 × 107 P. berghei infected erythrocytes intra-
peritoneally and 72 h later thin blood films were prepared 
to determine the level of parasitaemia.
% Parasitemia =
Number of Parasitized RBC







Determination of packed cell volume
Packed cell volume (PCV) was measured to predict the 
effectiveness of the test extract in preventing haemoly-
sis resulting from increased parasitaemia. Heparinized 
capillary tubes were used for collection of blood from 
tail of each mouse. The capillary tubes were filled with 
blood up to 3/4th of their volume and sealed at the dry 
end with sealing clay. The tubes were then placed in a 
micro-haematocrit centrifuge (Gelma Awhksley, Eng-
land) with the sealed end outwards and centrifuged for 
5  min at 12,000  rpm. The tubes were then taken out of 
the centrifuge and PCV was determined using a standard 
micro-haematocrit reader. PCV is a measure of the pro-
portion of RBCs to plasma and measured before inocu-
lating the parasite and after treatment using the following 
relationship:
Monitoring body weight
In the 4-day suppressive test, body weight of each 
infected mice was measured before infection on day 0 
and after treatment on day 4. However, for Rane’s test the 
body weight was measured after infection on day 3 and 
after treatment on day 7. The body weight of each mouse 
was measured using a sensitive digital weighing balance 
(Mettler Toledo, Switzerland).
Determination of rectal temperature
In a 4-day suppressive test, the body temperature of each 
mouse was determined before infection on day 0 and 
after treatment on day 4 using digital thermometer.
Monitoring mean survival time
In all of the in  vivo antiplasmodial models, mortality 
was monitored and the number of days from the time of 
inoculation of parasite up to death was recorded for each 
mouse in the treatment and control groups for 30 days. 
The mean survival time (MST) for each group was calcu-
lated as follows:
Data analysis
Data were analysed using Graph Pad Prism v 6.02. Com-
parisons were made among negative and positive con-
trols as well as treatment groups using a one-way analysis 
of variance (ANOVA) followed by Tukey’s multiple com-
parison tests. Mean PCV, rectal temperature and body 
weight before and after infection and treatment were 
compared by two tailed paired t test. The result was con-
sidered statistically significant at 95% confidence level 
and P < 0.05.
PCV =
Volume of Erythrocytes in a Given Volume of Blood
Total Blood Volume
MST =
Sum of Survival Time of All Mice in a Group (days)
Total Number of Mice in the Group
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Results
Acute oral toxicity assessment
In the in vivo acute toxicity studies of the plant extract, 
there were no gross physical and behavioural changes 
such as rigidity, sleep, diarrhoea, depression, abnormal 
secretion and hair erection for 24 h. All the mice survived 
within the 2-week observation period.
Sub‑acute oral toxicity assessment
The direct toxic effects of the crude extract on body 
weight and blood parameter (PCV) in healthy mice were 
evaluated by administering higher doses of the extract 
for 4 days. All hydroethanolic crude extracts of the three 
plants showed no statistically significant reduction in 
PCV on day 3 as compared to day 0 (Table  1) in non-
infected normal mice. In any of the doses, no mortal-
ity and insignificant difference in body weight was seen. 
However, significant (P  <  0.05) body weight gain was 
observed with 500 mg/kg of A. remota. 
In vivo assays
Four‑day suppressive effect
The percentage suppression analysis of the extract 
showed decrease (P  <  0.05) in parasitaemia at all dose 
levels as compared to the negative control group. The 
group received 100 mg/kg of the extract exhibited maxi-
mal suppression (77.54%) of parasitaemia than the other 
groups (Fig.  1). All doses of the extract significantly 
enhanced the survival time of the mice in a dose depend-
ent manner as compared to the negative control group; 
though the effect was significantly lower than the group 
which received chloroquine (Table 2).
Effect on body weight, PCV and temperature
Hydroethanolic crude extract of A. remota prevented sig-
nificant reduction of body weight on day 4 as compared 
to day 0 at all dose levels. On day 4, the percent change in 
body weight increment seemed almost dose dependent. 
In addition to that, the crude extract averted significant 
loss of PCV between days 0 and 4 at all dose levels. The 
negative control group showed significant loses of body 
weight and PCV (P < 0.05) on day 4. In the chloroquine 
treatment group, no significant change in both weight 
and PCV was observed (Table 3).
Analysis of rectal temperature of P. berghei infected and 
treated mice indicated that crude extract of A. remota 
prevented significant loss of body temperature at 50 and 
100 mg/kg dose levels on day 4. However, 30 mg/kg dose 
Table 1 Sub-acute toxic effects of  hydroethanolic crude 
extracts of Ajuga remota
Results are expressed as mean ± SEM (n = 5)
NC negative control, PCV packed cell volume
* There is significant difference at P < 0.05 between day 0 and day
Treatment Dose 
(mg)
Parameters Day 0 Day 3
Crude extract NC Body weight (g) 28.8 ± 0.37 30.20 ± 1.28
PCV (%) 51.00 ± 2.92 51.20 ± 1.59
500 Body weight (g) 27.32 ± 0.21 28.40 ± 0.24*
PCV (%) 49.40 ± 0.24 48.92 ± 0.69
750 Body weight (g) 28.18 ± 0.67 27.70 ± 0.95
PCV (%) 51.90 ± 1.49 51.16 ± 1.44
1000 Body weight (g) 31.04 ± 0.99 29.28 ± 1.57
PCV (%) 49.94 ± 0.45 49.82 ± 0.83
Fig. 1 Four day parasitaemia suppressive effect of different doses of 
crude extract of Ajuga remota as compared to the negative control 
(NC) and the standard treatment, chloroquine (CQ)
Table 2 Average parasitaemia and  mean survival time 
of hydroethanolic crude extracts of Ajuga remota
% parasitaemia and survival time results presented as mean ± SEM; n = 6
NC, negative control; CQ, chloroquine
*  Values are significantly different at P < 0.05
a Compared to negative control
b Compared to 30 mg/kg
c Compared to 50 mg/kg
d Compared to 100 mg/kg
Treatment Dose (mg/kg) % Parasitaemia Survival time 
(days)
Crude extract NC 32.15 ± 0.66 7 ± 0.86
30 14.82 ± 0.98*,a,c,d 11 ± 1.13*,a
50 10.59 ± 0.69*a,b,d 17 ± 1.00*a
100 7.22 ± 0.57*,a,b,c 18 ± 0.73*,a
CQ 0.00 ± 0.00*,a,b,c,d 29 ± 0.73*,a
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level of the crude extract; could not avert loss of body tem-
perature on day 4. The control group treated with vehicle 
showed significant (P < 0.05) loss of temperature on day 4. 
But, the group treated with the standard drug, chloroquine 
maintained their temperature on day 4 (Fig. 2).
Curative effect (Rane’s Test)
In curative potential evaluation of A. remota crude 
extract, all the three doses significantly reduced (P < 0.05) 
parasitaemia level on day 7 as compared to day 3. Para-
sitaemia reduction showed a dose dependent trend rela-
tive to the vehicle. On day 7, the highest parasitaemia 
suppression of 66.67% was seen by 100 mg/kg dose of the 
extract (Fig. 3). Survival time prolongation was observed 
at 50 and 100 mg/kg of the extract. No apparent survival 
time difference was observed between the group treated 
with vehicle and 30  mg/kg of the extract. Chloroquine-
treated group showed total eradication of the established 
P. berghei infection on day 7. However, no curative effect 
Table 3 Effect of hydroethanolic crude extract of Ajuga remota on body weight and PCV of Plasmodium berghei infected 
mice in 4 day suppressive test
Results presented as mean ± SD; n = 6
% ∆W, increment in weight; % ∆PCV, % increment in packed cell volume
* Significant difference between Day 0 and Day 4 (P < 0.05)
Treatment Dose (mg/kg) Body weight in grams Packed cell volume
Day 0 Day 4 % ∆W Day 0 Day 4 % ∆PCV
Crude extract NC 23.0 ± 1.09 21.0 ± 1.55* −8.69 54.0 ± 2.61 49.0 ± 1.58* −9.26
30 24.1 ± 1.61 23.3 ± 1.88 −3.32 53.0 ± 1.47 51.0 ± 4.16 −3.77
50 22.0 ± 0.89 22.3 ± 1.17 1.36 54.0 ± 6.07 52.33 ± 7.05 −3.09
100 23.2 ± 1.39 23.7 ± 0.93 2.16 52.0 ± 6.17 51.33 ± 2.94 −1.28
CQ 25.0 ± 1.77 25.8 ± 0.91 3.20 51.0 ± 2.41 50.83 ± 2.35 −0.33
37.2 37.5 37.1 37.2 37 
34.2 
36.1 
36.9 37.1 37 











Ajuga remota crude extract 
Day 0 Day 4
Fig. 2 The effect of hydroethanolic leaf extract of Ajuga remota on 
rectal temperature of P. berghei infected mice between day 0 and 4 in 
suppressive test. NC negative control, CQ chloroquine
Fig. 3 Curative effect of different doses of crude extract of Ajuga 
remota on day 7 as compared to the negative control (NC) and the 
standard treatment, chloroquine (CQ)
Table 4 Average parasitaemia and  mean survival time 
of  hydroethanolic crude extract of  Ajuga remota in  the 
Rane’s Test
% parasitaemia and survival time results presented as mean ± SEM; n = 6
NC, negative control; CQ, chloroquine
* Values are significantly different at P < 0.05 between day 3 and day 7
Treatment Dose  
(mg/kg)
Average  % parasitaemia Survival 
time
Day 3 Day 7
Crude 
extract
NC 19.33 ± 1.88 33.60 ± 0.97 7.33 ± 0.56
30 21.67 ± 1.53 17.33 ± 0.80* 7.83 ± 1.01
50 24.40 ± 1.93 13.50 ± 0.69* 13.00 ± 0.37*
100 23.50 ± 2.84 11.20 ± 0.35* 16.67 ± 0.76*
CQ 22.70 ± 0.73 0.00 ± 0.00* 29.00 ± 0.58*
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was shown by any of the test group treated with different 
doses of the extract unlike chloroquine (Table 4).
In evaluating effect of A. remota on body weight in 
the curative test, there was significant body weight loss 
(P  <  0.05) at 30 and 50  mg/kg doses of the extract on 
day 7 as compared to day 3. The 100 mg/kg dose of the 
extract prevented significant loss of body weight on day 
7. Vehicle administered group showed significant loss of 
body weight. On the contrary, chloroquine treated group 
did not exhibit significant weight loss (Fig. 4).
Prophylactic effect
In the residual test, the activity of the extract was signifi-
cant on day 8 (P < 0.05), at the tested doses of 30, 50 and 
100  mg/kg/day. They produced 47.22, 51.53 and 59.66% 
suppression of parasitaemia, respectively (Fig. 5). However, 
significant prolongation of survival time was observed at 
the highest dose of the extract (100 mg/kg/day) (Table 5).
Discussion
Ajuga remota is widely applied in the folkloric medicine 
of Ethiopia for treating various types of disorders [17]. 
Plant medicines has been utilized by majority of the 
world population for primary health care [18]. However, 
lack of validated information has been a major concern 
with respect to the use of plant medicines [19].
The results of the acute toxicity of A. remota revealed 
that there was no mortality observed up to the maxi-
mum dose level of 2000 mg/kg body weight of the extract 
administered orally, where single high dose is recom-
mended for testing acute toxicity [12]. No behavioural 
changes were observed either viz apathy and reduced loco-
motors activity. Accordingly, 2000  mg/kg of each plant 
extract was found safe, i.e., the approximate median lethal 
dose (LD50) of the extracts in the experimental mice was 
higher than 2000 mg/kg. The results observed in the acute 
toxicity study with A. remota is in agreement with those 
of the previous study [20]. The reduction in body weight 
gain is a simple and sensitive index of toxicity after expo-
sure to toxic substances [21]. In sub-acute toxicity study, 
all the groups treated with 500, 750 and 1000 mg/kg doses 
of the crude extract did not show significant change in 
weight on day 4 as compared to day 0 except the group 
received 500  mg/kg of the extract which showed signifi-
cant (P < 0.05) body weight gain on day 4. This observation 
indicates that the crude extracts may not contain appetite 
















Ajuga remota  crude extract 
Day 3 Day 7
Fig. 4 The effect of hydroethanolic crude extract of Ajuga remota on 
body weight of P. berghei infected mice in curative test. NC negative 
control, CQ chloroquine
Fig. 5 Parasitaemia suppressive effect of different doses of crude 
extract of Ajuga remota on day 8 as compared to the negative control 
(NC) and the standard treatment, chloroquine (CQ) in the prophylac-
tic test
Table 5 Average parasitaemia and survival time of hydro-
ethanolic crude extract of  Ajuga remota in  P. berghei 
infected mice in prophylactic test
% parasitaemia and survival time results presented as mean ± SEM; n = 6
NC, negative control; CQ, chloroquine
*  Values are significantly different at P < 0.05
a Compared to negative control
b Compared to 30 mg/kg
c Compared to 50 mg/kg
d Compared to 100 mg/kg







Crude extract NC 36.32 ± 1.57 7.83 ± 0.17
30 19.17 ± 1.28*,a 8.83 ± 0.48
50 17.60 ± 1.53*,a 9.18 ± 0.31
100 14.65 ± 0.64*,a 10.33 ± 0.67*
CQ 0.00 ± 0.00*,a,b,c,d 28.67 ± 0.56*
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stimulant compounds [22]. Study on haematological 
parameters is important to discriminate the toxic effects of 
exogenous compounds on animals [23]. In this study, PCV, 
an index of anaemia, did not show significant difference on 
day 4 as compared to day 0 of either treated or untreated 
mice. This might indicate the safety nature of the extract.
In vivo models are usually applied in antimalarial stud-
ies for they allow the possible prodrug effect and likely 
boosting of the immune system in eradication of the 
infectious agent [24]. In the four-day parasitaemia sup-
pression study, treatment of mice with crude extract of A. 
remota reduced the erythrocytic stage development of P. 
berghei. Parasitaemia was suppressed in a dose depend-
ent manner indicating that the plant has antimalarial 
activity. Similar results were obtained in studies reported 
from the same species of A. remota [25]. The parasite 
suppressive effect of plant extract might be through indi-
rect boosting of the immune system or by inhibition of 
other target pathways which are not fully realized [26]. 
Likewise, the parasite inhibitory effect of the extract with 
unknown compounds might be attributed to the antiplas-
modial activity of specific compound or group of com-
pounds [27]. Ajuga remota possesses compounds such as, 
terpenoids, sterols, flavonoids and saponins that might 
be responsible for its antiplasmodial activity [8–10].
The mean survival time is important to evaluate the 
anti-malarial activity of plant extracts [28]. The extract 
prolonged survival time of mice at all dose levels which 
is associated with suppression of parasitaemia. Haema-
tological abnormalities like anaemia, body weight loss 
and temperature reductions are common character-
istics of P. berghei infected mice [29]. Plants with anti-
malarial activity are expected to prevent body weight 
loss in infected mice resulting from rise in parasitaemia. 
The crude extract of A. remota significantly prevented 
body weight loss in a dose dependent manner on day 
4 as compared to day 0. Plasmodium berghei infected 
mice showed decrease in metabolic rate before death 
which as a result caused drop in internal body tempera-
ture [30]. Thus, plant extracts with anti-malarial activ-
ity must prevent rapid falling of body temperature [29]. 
Crude extract of A. remota prevented body temperature 
drop at 50 and 100 mg/kg doses on day 4 as compared 
to day 0.
Rodent malaria causes parasite-induced fall of PCV, 
which occurred approximately 48  h post-infection [29]. 
Plasmodium berghei infected mice suffer from anaemia 
because of erythrocyte destruction, either by parasite 
multiplication or by spleen reticuloendotelial cell action 
as the presence of many abnormal erythrocytes stimu-
lates the spleen to produce many phagocytes [22]. All of 
these mechanisms are accountable to malaria induced 
anaemia both in mice and men [31]. It was noted that 
crude extract of A. remota prevented reduction in PCV 
at all dose levels in between day 0 and day 4. Though A. 
remota contains saponins [8, 10] responsible for haemo-
lytic effects, the sub-acute toxicity study done in healthy 
non-infected mice confirmed that the crude extract did 
not cause haematological abnormalities (PCV reduction). 
PCV reduction and body weight loss preventive effect of 
the hydroethanolic crude extract of A. remota in infected 
mice is consistent with the sub-acute toxicity study car-
ried out in healthy non-infected mice. This confirms that 
the plant extract has no impact on the measured param-
eters. The preventive effect of haematological abnor-
malities (PCV reduction), body weights lose and rectal 
temperature drop by the crude extract of A. remota infer 
its antimalarial activity.
In the curative test, crude extract of A. remota did 
not eradicate parasites completely on day 7. How-
ever, it showed parasite suppressive effects. Com-
plicated syndromes of malaria comprise of many 
inflammatory mediators which may enhance cell to cell 
interaction (cytoadherence), cell stimulation through 
malaria-derived antigens and host-derived factors like 
cytokines. Cytokines are also responsible to cause fever 
in the host [32]. The curative antiplasmodial properties of 
A. remota may be due to the inhibition of the production 
and/or release of these inflammatory mediators associ-
ated with malaria. Surprisingly, A. remota is traditionally 
used for its pain and fever reduction ability [7, 8, 33].
In the prophylactic assay, A. remota resulted in better 
efficacy than the negative control on day 8. The probable 
mechanism to produce prophylactic activity on P. berghei 
infection might be inhibiting proliferation of parasites due 
to direct cytotoxic effect [34] and modulation of the mem-
brane of the erythrocytes preventing parasite invasion [35].
In vivo antiplasmodial activity can be classified as 
moderate, good, and very good if an extract displayed 
percentage parasitaemia suppression equal to or greater 
than 50% at a dose of 500, 250 and 100  mg/kg body 
weight per day, respectively [36]. Based on this classifi-
cation, the crude extract of A. remota showed very good 
antiplasmodial activity below 100  mg/kg/day dose level. 
Similarly, four day suppressive in  vivo evaluation of the 
wet and dried leaf aqueous extracts of A. remota showed 
90.35 and 82.82% suppression of parasitaemia, respec-
tively [25].
Conclusions
This investigation confirmed that A. remota has anti-
malarial activity in the in vivo model. The results of the 
present study, therefore, likely support the traditional use 
of this plant in Ethiopia.
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